Syed Riaz, MD
Critical Care Medicine · Marlton, NJNPI 1104072727
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (48.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Intuitive Surgical at 57.4% of the total. Reporting peaked in 2024 at $7,019 and has fallen 84.3% since, to $1,102 in 2025. Among critical care medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $98.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Noah Medical Corporation$2K
- Covidien LP$885
- GSK$405
- Pulmonx Corporation$332
- Regeneron Healthcare Solutions, Inc.$312
- plus $752 from 16 others
What the payments were for
- Travel & lodging$3,78333%
- Food & beverage$2,16819%
- Education$5,59948%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $6,634 |
| Noah Medical Corporation | 11 | $2,229 |
| Covidien LP | 3 | $885 |
| GSK | 29 | $405 |
| Pulmonx Corporation | 8 | $332 |
| Regeneron Healthcare Solutions, Inc. | 12 | $312 |
| AstraZeneca | 8 | $188 |
| Harmony Biosciences LLC | 5 | $85 |
| Insmed, Inc. | 4 | $73 |
| Verona Pharma, Inc. | 3 | $57 |
| Genentech USA, Inc. | 3 | $53 |
| Actelion Pharmaceuticals US, Inc. | 3 | $47 |
| Sanofi | 2 | $40 |
| Boehringer Ingelheim | 2 | $37 |
| Amgen | 2 | $33 |
| Johnson & Johnson | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Grifols USA, LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $14 |
| Veran Medical Technologies, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,551 in reported general payments places this provider in the 95th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $101,610 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $32,931 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $32,683 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $20,590 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,685 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $7,114 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 217 | $5,963 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $3,445 |
| Ventolin HfaAlbuterol Sulfate | 27 | $1,444 |
| Azelastine Hcl | 25 | $912 |
| Fluticasone Propionate | 32 | $810 |
| Montelukast Sodium | 46 | $441 |
| Ipratropium Bromide | 14 | $406 |
| Prednisone | 47 | $161 |
| Azithromycin | 19 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $405 | $187,813295 claims |
| AstraZenecaBreztri Aerosphere | $188 | $10,68517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Marlton
- Neha VagadiaMarlton$31K
- Aaron CrookshankMarlton$8K
- Emilio MazzaMarlton$7K
- Eric SztejmanMarlton$6K
- Jonathan GalliMarlton$5K
- Rohit MalikMarlton$5K
- Angel RodisMarlton$4K
- Andrew SchiffMarlton$4K
- Roman KrolMarlton$4K
- Brian JaffeMarlton$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.